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Wiley J. Youngs,a David A. Hunstadb,d
Department of Chemistry and Center for Silver Therapeutics Research, University of Akron, Akron, Ohio, USAa; Department of Pediatrics, Washington University, St. Louis,
Missouri, USAb; Department of Chemistry, Department of Chemical Engineering, and Department of Materials Science and Engineering, Texas A&M University, College
Station, Texas, USAc; Department of Molecular Microbiology, Washington University, St. Louis, Missouri, USAd
We present a novel family of small-molecule urinary bladder exfoliants that are expected to be of great value in preclinical stud-
ies of urologic conditions and have improved potential for translation compared with prior agents. There is broad urologic in-
terest in the therapeutic potential of such exfoliating agents. The primary agent used in preclinical models, the cationic peptide
protamine sulfate (PS), has limited translational potential due to concerns including systemic adverse reactions and bladder tis-
sue injury. Intravesical application of a safe, systemically nontoxic exfoliant would have potential utility in the eradication of
Escherichia coli and other uropathogens that reside in the bladder epithelium following cystitis, as well as in chronic bladder
pain and bladder cancer. Here, we introduce a family of imidazolium salts with potent and focused exfoliating activity on the
bladder epithelium. Synthesis and purification were straightforward and scalable, and the compounds exhibited prolonged sta-
bility in lyophilized form. Most members of the compound family were cytotoxic to cultured uroepithelial cells, with>10-fold
differences in potency across the series. Upon topical (intravesical) administration of selected compounds to the murine bladder,
complete epithelial exfoliation was achieved with physiologically relevant imidazolium concentrations and brief contact times.
The exfoliative activity of these compounds was markedly improved in comparison to PS, as assessed by microscopy, immuno-
fluorescence, and immunoblotting for uroplakins. Bladder uroepithelium regenerated within days to yield a histologically nor-
mal appearance, and no toxicity was observed. Finally, the chemical scaffold offers an opportunity for inclusion of antimicrobi-
als or conjugation with chemotherapeutic or other moieties.
The urinary bladder in highermammals is uniquely formed andstructured to collect filtered waste products from the kidneys
and to provide ameans for retention and storage of thiswaste until
micturition is convenient for the animal. The bladder lumen is
lined by a multilayered, pseudostratified transitional epithelium,
underlain by the basement membrane and lamina propria.
Smooth muscle deep to this, under parasympathetic neural influ-
ence, directs contraction of the bladder, which in conjunction
with sphincter relaxation allows for controlled micturition. Im-
portantly, the tissues of the bladder are protected from potentially
toxic effects of urine components by a highly ordered array of
uroplakins, glycoproteins which coat the apical surfaces of super-
ficial bladder epithelial cells (also termed facet or umbrella cells)
and comprise an impermeable barrier to urine and its solutes (1).
These uroplakins are decorated with mannose moieties, which
are co-opted as receptors for binding by uropathogenic Esche-
richia coli (UPEC), the chief cause of urinary tract infections (UTI)
(2). Bacterial binding to mannosylated uroplakin is the initiating
event of cystitis (3, 4) and leads to the internalization of UPEC by
superficial bladder epithelial cells during acute bacterial cystitis in
murine and human hosts (5–8). These cells serve as a protected
niche for UPEC to replicate while sheltered from the phagocytic
activity of neutrophils summoned in response to infection (9).
Exfoliation of the superficial cell layer is observed later in the acute
phase and represents a host defense mechanism capable of elimi-
nating large numbers of replicating bacteria (7, 10). However, this
process also exposes additional cells to infection, as facet cell ex-
foliation triggers underlying cells to initiate expression of uro-
plakins (11). When the acute phase of experimental cystitis has
resolved, many hosts remain infected with a small number of or-
ganisms residing in quiescent intracellular reservoirs within su-
perficial epithelial cells (10). These bacteria apparently resist im-
mune clearance and are not eliminated by systemic antibiotic
therapy (12–14). As these bacteria are thought to serve as a seed for
recurrent cystitis caused by the same strain (15, 16), there is inter-
est in developing novel strategies for their eradication.
One concept for such a strategy is intentional exfoliation of the
superficial epithelial layer, which would eliminate many resident
bacteria in the urine and force the emergence of remaining reser-
voir bacteria into the luminal compartment, where systemically
administered antibioticsmight be effective (15). Though there are
few data to confirm the effectiveness of this concept, one exfolia-
tive agent has predominated in use in a variety of preclinical mod-
els for conditions other than UTI (e.g., chronic bladder pain, in-
terstitial cystitis). This agent, protamine sulfate (PS), is an
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5-kDa representative of a family of arginine-rich cationic pep-
tides isolated fromfish sperm; in humans, recombinant PS is given
intravenously for reversal of heparin-based anticoagulation. Im-
portantly, systemic administration of PS in humans can provoke
significant allergic (IgE-mediated) and anaphylactoid reactions in
several patient populations, including diabetics and infertile men
(17–20). Its application inmoderate to high concentrations to the
mouse or rat bladder elicits substantial loss of superficial epithelial
cells (21–23), and it has been used in combination with other
irritants (e.g., lipopolysaccharide) in models of chronic bladder
inflammation (24–26). Further pursuit of combined strategies
targeting chronically resident uropathogens, therefore, would
benefit greatly from an optimized exfoliant.
We sought to identify and develop small-molecule topical in-
travesical agents exhibiting enhanced exfoliative effects andhigher
potency while requiring short contact time and inducingminimal
local inflammation. Here, we present a series of imidazolium salt
derivatives demonstrating a cytotoxic effect after limited incuba-
tionwith cultured bladder transitional epithelial cells. Several rep-
resentative compounds from this series, selected on the basis of
their in vitro activity, were shown to induce near-complete exfo-
liation of the bladder superficial epithelial cell layer in murine
hosts, without overt inflammatory changes or apparent injury to
underlying cells. It is expected that these imidazolium salts will
prove to be useful in preclinical studies of bladder biology while
also holding promise as adjunctive therapeutics for chronic and
recurrent UTI. The compounds exfoliate the mammalian bladder
rapidly, safely, and effectively and can be adapted structurally to
carry other biocides (e.g., silver moieties) in a combined agent. In
addition, the chemical backbone provides a tractable platform for
future diagnostic and therapeutic application to other urinary
tract conditions, such as bladder epithelial cancers.
MATERIALS AND METHODS
Imidazolium compounds.All reagents and solvents used in the synthesis
of the compounds were purchased from commercial sources and used
without purification with the exception of 2-(chloromethyl)-6-me-
thoxynaphthalene, which was synthesized according to a published
FIG 1 Synthetic scheme for imidazolium salts, compounds 1 to 7 (top row), compound 8 (middle row), and compound 9 (bottom row). The identities of
substituents R1 through R5 in these compounds are indicated in the table, using abbreviations for substituent groups as indicated below the table. Abbreviations:
Hex, hexyl; Quin, quinolyl; Nap, naphthyl; NapOMe, 6-methoxynaphthyl; DEO, di(ethyleneoxide).
Imidazolium Salts as Bladder Exfoliants
September 2015 Volume 59 Number 9 aac.asm.org 5495Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 29, 2015 by W
ashington University in St. Louis
http://aac.asm
.org/
D
ow
nloaded from
 
method (27). Column chromatography utilized silica gel (60 Å; ICN
Medicals) embedded with fluorescence indicator green 254 nm (Fluka
Analytical).Melting pointswere determined on aMelTemp apparatus. 1H
and 13C{1H} nuclear magnetic resonance (NMR) spectra were collected
on aVarian instrument operated at 500MHz for 1H and 125MHz for 13C,
with all spectra referenced to residual solvent protons or the 13C signal in
dimethyl sulfoxide-d6 (DMSO-d6) (Cambridge Isotope Laboratories)
(  2.50 ppm or 39.51 ppm, respectively). Mass spectrometry was per-
formed by the University of Akronmass spectrometry laboratory (Akron,
OH). Elemental analysis was performed by AtlanticMicrolabs, Inc. (Nor-
cross, GA) or by the University of Akron Department of Geology (Ak-
ron, OH).
Single crystals of compounds 3 to 6 and 8 were coated in paratone oil,
mounted on a CryoLoop, and placed on a goniometer under a stream of
nitrogen. Crystal structure data sets were collected with a Kappa APEX II
SuperDuo charge-coupled-device (CCD) system (Bruker AXS Inc., Mad-
ison, WI) equipped with a Mo ImuS source (  0.71073 Å) and a Cu
ImuSmicrofocus source equippedwithQUAZARoptics ( 1.54178Å).
Unit cells were determined by using reflections from three different ori-
entations. Data sets were integrated using SAINT (Bruker). An empirical
absorption correction and other corrections were applied to the data sets
using multiscan SADABS (Bruker). Structure solution, refinement, and
modeling were accomplished by using the Bruker SHELXTL software
package (28). The structures were determined by full-matrix least-squares
refinement of F2 and the selection of the appropriate atoms from the
generated difference map. Hydrogen atom positions were calculated and
Uiso(H) values were fixed according to a riding model.
Lyophilized compounds were stored in ambient conditions on the
benchtop until the day of use. Compounds were dissolved in dimethyl
sulfoxide (Sigma) and then brought up to a working concentration of 1
mM in sterile molecular biology-grade water (Fisher) (final concentra-
tion, 1% DMSO). For mouse inoculations, compounds were diluted to
800Minwater. For tissue culture experiments, compoundswere diluted
from the working 1mM stock in RPMI 1640medium (Gibco) containing
10% fetal bovine serum (FBS) (Sigma). Protamine sulfate (PS) (Sigma)
(50 mg/ml in water) was used as an established comparator method for
bladder epithelial exfoliation (29), and 0.8% DMSO in water was used as
a vehicle-only control.
Cell viability assays. Human bladder epithelial cells (5637 [ATCC
HTB-9]; American Type Culture Collection) were maintained in RPMI
1640 medium with 10% FBS. The viability of cultured cells was analyzed
by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (TACS; Trevigen) according to the manufacturer’s instruc-
tions. Briefly, cells were plated (5 104 per well) and grown to confluence
at 37°C with 5% CO2. On the day of the experiment, the medium was
removed, and compounds and controls (in medium as described above)
were added at the indicated doses. Following 15- or 60-min incubation,
treatmentmediumwas removed; cells were incubated with freshmedium
containing the MTT reagent at 37°C for 3 h, until an intracellular purple
precipitate was visible by microscopy. Detergent was then added to each
well, and plates were kept at room temperature in the dark overnight.
Absorbance at 570 nm was measured on a BioTek Synergy 2 microplate
reader, and cell viability was determined by subtracting blanks and divid-
ing the A570 value of treated cells by cells incubated with medium only.
FIG 2 Chemical structures of compounds 1 to 9.
FIG3 Dose-dependent effects of imidazolium salts on the viability of cultured
uroepithelial cells. Bladder epithelial cells were treated for 60 min with the
indicated concentrations of compounds 1 through 9, and viability was mea-
sured by a standard MTT assay. Relative cytotoxicity, normalized to that of
untreated cells lysed subsequently with detergent, of each compound and dose
is shown. Values are means  standard deviations (SD) (error bars). Com-
pounds 2 and 9 displayed the highest potency, while compound 5 induced
cytotoxicity only at the highest tested concentration. Data are representative of
two or three independent experiments per compound, with triplicate wells.
Data from 15-min incubations are given in Fig. S2 in the supplemental
material.
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Data shown are representative of two or three independent experiments
per compound, with triplicate wells.
Mice. All animal procedures were done with prior approval from the
Animal Studies Committee at Washington University. Female C57BL/6
mice 7 to 8 weeks of age (Jackson Laboratories) were anesthetized with
inhaled isoflurane, and 50l of compound or control was delivered to the
bladder via transurethral catheterization (30). Anesthesia wasmaintained
for 15 min following administration to decrease the chance of immediate
voiding of bladder contents. A second dose was similarly administered
12.5 h after the initial inoculation. Mice were euthanized after 16 h of
compound exposure (3.5 h after the second inoculation), a schedule based
on recent studies with PS (29).
Immunoblotting. Exfoliation was quantified by blotting bladder ho-
mogenates for epithelial uroplakins using methods we developed previ-
ously (31). Briefly, bladders were harvested aseptically and homogenized
in a bead beater (Bullet Blender Storm 2.4; Next Advance, Inc.) using
sterile stainless steel beads. Homogenates were stored long-term at
	80°C, and working aliquots were diluted in SDS loading buffer and
maintained at 	20°C. Prior to blotting, homogenates were thawed and
loaded without boiling into 12% SDS-polyacrylamide gels. The samples
were then semidry transferred to polyvinylidene difluoride (PVDF)mem-
branes, blocked in 2% dry milk with 2% bovine serum albumin (BSA) in
blocking buffer (0.5% Tween 20, 3% sodium chloride, 0.13% Tris base
[pH 8.2]), and probed for uroplakin la (UPIa) (SC-15173; Santa Cruz
Biotechnology) (diluted 1:250) and actin (SC-1616; Santa Cruz Biotech-
nology) (1:400) or for uroplakin III (UPIII) (SC-33570; Santa Cruz Bio-
technology) (1:2,000) and CoxIV (4844S; Cell Signaling) (1:4,000). Dif-
ferent control proteins were used for the parallel Western blots so that,
given themolecular weights, the bands could be clearly imaged and quan-
tified. Alkaline phosphatase-conjugated anti-goat IgG (Sigma) (1:1,000)
or anti-rabbit IgG (Sigma) (1:2,000) was used as a secondary antibody,
respectively. Blots were developed with Tropix CDP-Star (Applied Bio-
systems) and exposed to film. Band density was quantified by ImageJ
analysis, and uroplakin levels were normalized to the loading control
bands (actin orCoxIV). Adjusted band densities were compared by paired
t test; P values of 
0.05 were considered significant. Data are from two
experiments completed in triplicate on different days with freshly pre-
pared compounds. Results were obtained from a total of six mice per
compound.
Histology. The bladders were removed aseptically and fixed in meth-
acarn (60% methanol, 30% chloroform, 10% acetic acid). The tissues
were then set in 2% agar, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin. Images were captured using an Olympus
DP25 camera and BX40 light microscope. For each compound included
in this analysis (compounds 2, 3, 5, and 9), two or three separate bladders
were examined and compared to multiple uninoculated, DMSO-treated,
and PS-treated bladders.
Immunofluorescence. Bladder sections were deparaffinized with
mixed xylenes and rehydrated with isopropanol prior to antigen retrieval
via boiling in 10 mM sodium citrate. Once the slides were cooled, they
were blocked with 1%BSA and 0.3%Triton X-100 in phosphate-buffered
saline (PBS) and then incubated with rabbit anti-uroplakin III (diluted
1:100) for 1.5 h. Following primary antibody removal, Alexa Fluor 488-
conjugated goat anti-rabbit antibody (catalog no. A11008; Life Technol-
ogies) (1:500) and Syto 61 (Molecular Probes) (1:1,000) were added to-
gether for 30 min at room temperature. Slides were mounted with
ProLong Gold (Invitrogen) and examined by epifluorescencemicroscopy
using a Zeiss Axioskop instrument. For each compound included in this
analysis (compounds 2, 3, 5, and 9), two or three separate bladders were
examined and compared to multiple uninoculated, DMSO-treated, and
PS-treated bladders.
FIG 4 Exfoliation of murine bladder epithelium upon treatment with selected imidazolium salts. Murine bladders were treated twice (12.5 h apart) with
protamine sulfate (PS) (50 mg/ml), vehicle only (DMSO), or compound 2, 3, 5, or 9 at 800 M. Uninoculated (Uninoc) bladders were also similarly analyzed.
(A to D) Exfoliation was assessed by adjusted relative density onWestern blots of whole-bladder homogenates for uroplakin Ia (A and B) or uroplakin III (C and
D). (A and B) Cumulative ImageJ quantitation (A) and a representativeWestern blot for UPIa with actin control (B). (C andD) Cumulative ImageJ quantitation
(C) and a representative Western blot for UPIII with CoxIV control (D). Compounds 2, 3, and 9 elicited statistically significant exfoliation compared with the
value for vehicle only (DMSO). Values that are significantly different from the value for vehicle only (DMSO) by paired t test are indicated by asterisks as follows:
*,P 0.02; **,P
 0.001.Data in panels A andC are derived from six ormoremice per treatment on two separate dayswith independent compoundpreparation.
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Cytokine analysis. Cytokine analysis was performed using the Bio-
Plex Pro mouse cytokine Th17 panel A 6-plex group I kit (Bio-Rad) with
magnetic beads following the manufacturer’s instructions. Undiluted
bladder homogenates were centrifuged at 10,000  g for 10 min at 4°C,
and cleared lysates were analyzed in duplicate wells (five mice in a group
for the uninoculated group and PS- and DMSO-treated groups; six mice
in a group for each group treated with compound 2, 3, 5, or 9). Data were
analyzed with BioPlexManager software according to the manufacturer’s
instructions.
RESULTS
Synthesis and characterization of a family of substituted imida-
zolium salts.Compounds 1 and 2were synthesized according to a
published procedure (32). To synthesize the remaining com-
pounds, the imidazole derivatives were alkylated in two steps (Fig.
1). For compounds 3 to 8, commercially available imidazole, 4,5-
dichloroimidazole, or benzimidazole was deprotonated by potas-
sium hydroxide in acetonitrile followed by the addition of the
respective alkyl halide (X-CH2-R
1) and heating at reflux to gener-
ate the monosubstituted intermediates, which were isolated and
characterized. To a solution of the intermediates in acetonitrile
was added the second alkyl halide (X-CH2-R
2), followed by heat-
ing at reflux to generate the corresponding imidazolium salts,
compounds 3 to 8, which precipitated from the reactionmixtures.
These salts were generated in 80 to 90% yields from themonosub-
stituted intermediates (with the exception of compound 3, which
was generated in 50% yield) and required minimal purification.
Compound 9 was synthesized by the same general procedure;
however, the monosubstituted intermediate was not isolated. The
starting imidazole derivative 2-((2-(2-methoxyethoxy)ethoxy)
methyl)benzimidazole was first synthesized by the overnight
reaction of o-phenylenediamine with 2-(2-(2-methoxyethoxy)
ethoxy)acetic acid at 140°C. This imidazole derivative was then
converted to the corresponding imidazolium salt, compound 9,
via deprotonation and two sequential additions of the corre-
sponding alkyl halides. All chemical intermediates were character-
ized by 1H and 13C{1H} NMR spectroscopy, and compounds 3 to
9 were characterized by multiple spectroscopic techniques to ver-
ify their structures and purities. Additionally, the structures of
compounds 3 to 6 and 8 were elucidated by X-ray crystallography.
The structures of compounds 1 to 9 are shown in Fig. 2. Full details
of the synthesis and characterization of the imidazolium salts (in-
cluding crystallographic data links) are provided in the supple-
mental material.
In vitro cytotoxic effects of substituted imidazolium salts. In
evaluating the potential utility of the compound series as urinary
exfoliants, we first assessed their cytotoxic effect on cultured 5637
bladder epithelial cells, using a standard cell viability (MTT) assay.
We aimed tomodel exposure times relevant to in vivo application,
based on dilution by continual arrival of urine into the bladder;
short intervals between micturition events (in the murine host);
and feasibility of potential treatment duration with a future, opti-
mized agent in human patients. Therefore, treatment intervals of
15 and 60 min were chosen, and a broad range of compound
concentrations were tested (0-800 M). Among the 9 com-
pounds, all demonstrated a dose-dependent and variably potent
impact on 5637 uroepithelial cell viability after 15min (see Fig. S2
FIG 5 Immunofluorescence microscopy of treated bladder sections for uroplakin III. After transurethral bladder treatment with protamine sulfate (PS) (50
mg/ml), 0.8% DMSO (vehicle), or compound 2, 3, 5, or 9 (800 M) as indicated, the bladders were harvested, fixed, sectioned, and processed using a
dual-antibody scheme for uroplakin III (green) and Syto 61 nuclear stain (red) as detailed inMaterials andMethods. DMSO-treated bladders appeared identical
to untreated bladders (not shown). While PS treatment showed patchy mild exfoliation, compounds 2 and 9 were strongly exfoliative (i.e., had little UPIII
staining), and compound 3 exerted a partial effect. Compound 5 treatment was nearly indistinguishable from vehicle-only (DMSO) treatment. Bar, 50 m.
Wagers et al.
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in the supplemental material) or 60 min (Fig. 3) of treatment.
Compounds 2 and 9 exhibited a marked cytotoxic effect at 50
M, while the effects of compounds 1 and 7 were evident at
100 M, and the effects of compounds 3 and 6 were evident at
200 M. Compound 5 displayed the least potent activity, in-
ducing significant cytotoxicity only at the highest concentra-
tion tested (800 M).
In vivo exfoliative activity of selected imidazolium salts. To
correlate these in vitro findings with potential in vivo activity, we
selected several compounds from the series for intravesical instil-
lation in mice. Compounds 2 and 9 were selected for their robust
in vitro activities, and compound 3 was selected for its moderate
activity (median at 100 M among the group); compound 5 was
chosen as a comparator, since compound 5 displayed substantially
less toxicity to cultured uroepithelial cells (Fig. 3). Each of these
compounds, at the highest in vitro-tested dose (800 M; chosen
because in vivo contact time could not be ensured past 15 min of
anesthesia), was applied to the bladder in a two-dose schedule
over 16 h, and exfoliation of superficial bladder epithelial cells was
assessed by multiple methods. ByWestern blotting of bladder ho-
mogenates for either uroplakin Ia or III (assessed independently),
instillation of vehicle only (DMSO) caused no measurable exfoli-
ation (Fig. 4). Protamine sulfate (50 mg/ml), the prototypic blad-
der epithelial exfoliant, elicited only 25% exfoliation as mea-
sured by this method. In contrast, compounds 2, 3, and 9 induced
near-complete exfoliation (P  0.02 versus the value for vehicle
only for these three compounds; Fig. 4). As predicted from our in
vitro results, compound 5 had little effect on uroepithelial cell
integrity (Fig. 4). Thus, trends among the compounds in in vivo
epithelial exfoliation were reflected in the in vitro cytotoxicity re-
sults.
To further delineate integrity of the mammalian bladder epi-
thelium upon exposure to these agents, we treated murine blad-
ders as outlined above, and fixed the bladders for immunofluores-
cence analysis using a primary antibody to mouse uroplakin III
(Fig. 5).Our resultswere consonantwith those produced byWest-
ern blotting quantification. Specifically, treatment with DMSO
only did not yield an appearance different from that of uninocu-
lated bladders (uninoculated histology not shown). PS treatment
resulted in moderate and patchy exfoliation, while application of
compound 2, 3, or 9 at 800 M caused near-complete exfoliation
(Fig. 5). Of note, early uroplakin expression by underlying cells
was evident by this time point (16 h), indicating initiation of epi-
thelial differentiation pathways (11). Meanwhile, compound 5
(800M)had no discernible effect on the integrity of the facet cell
layer.
Bladder tissue responses to imidazolium treatment. To dis-
cern inflammatory or other effects on bladder tissue upon expo-
sure to imidazolium compounds, we inoculated mice as outlined
above and fixed and stained sections of treated bladders with he-
matoxylin and eosin in standard fashion. The histology ofDMSO-
treated bladders was normal (Fig. 6), as was that of uninoculated
bladders (not shown). PS treatment led to patchy epithelial loss,
while compounds 2 and 9 yielded complete exfoliation of the ep-
ithelium. Compound 3 yielded incomplete exfoliation, while
compound 5 had no histologically evident effects. Of note, treat-
FIG6 Histology of treated bladder sections. Bladderswere treated in vivowith protamine sulfate (PS), 0.8%DMSO (vehicle), or compound 2, 3, 5, or 9 (800M)
as indicated. Standard hematoxylin-and-eosin staining of fixed sections indicates scattered superficial epithelial loss with PS treatment, while DMSO treatment
had no effect compared with untreated bladders (not shown). Treatment with compound 2 or 9 resulted in near-complete or complete exfoliation of the
transitional epithelial cells, while compound 3 exhibited a partial effect. With this dosing and analysis schedule, evidence of inflammatory response (edema,
cellular infiltrate) was not observed. Again, treatment with compound 5 had little effect on the histologic appearance of bladder sections. Bar, 50 m.
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ment with the exfoliative imidazolium salts (compound 2, 3, or 9)
elicitedminimal to no cellular infiltrate or edema and no apparent
cytotoxicity beyond the basementmembrane (Fig. 6). In addition,
levels of interleukin 1 (IL-1), IL-6, IL-10, IL-17A, tumor necro-
sis factor alpha (TNF-), or gamma interferon (IFN-) in bladder
homogenates were not significantly changed after treatment with
any of the compounds (data not shown). To assess epithelial re-
covery from exfoliation, we examined bladders harvested from
mice 1 week following treatment as outlined above with the exfo-
liant PS or exfoliant compound 2, 3, or 9. All treated bladders
exhibited a regenerated uroepithelium that was histologically nor-
mal in appearance, including restoration of the facet cell layer
(Fig. 7).
DISCUSSION
There is a need in preclinical urologic studies for small-molecule
agents that will efficiently achieve exfoliation of the urinary blad-
der. Protamine sulfate, the most widely used bladder epithelial
exfoliant, is a relatively large molecule (5 kDa) and, with many
published application strategies, achieves incomplete epithelial
exfoliation. Here, we present a novel series of imidazolium salts
with different levels of potency in cytotoxicity to cultured uroepi-
thelial cells and in exfoliative activity in the murine bladder. The
compounds displaying the most potent in vitro cytotoxicity were
also those with the most exfoliant activity in vivo; similar trends
were observed across the compound series. Even the most potent
exfoliators in this family remained safe, inducing no discernible
systemic effects and allowing regeneration of the bladder epithe-
lium within days. The chemical scaffold also enables conjugation
and modification for a variety of experimental and potentially
translatable applications.
Among these potential applications, there is recently burgeon-
ing interest in bladder epithelial exfoliation as adjunctive therapy
in chronic and recurrent urinary tract infection. As noted in the
introduction, acute UPEC cystitis relies critically on rapid bacte-
rial replication within the cytoplasm of superficial bladder epithe-
lial cells, a niche that is protective against the phagocytic activity of
arriving neutrophils. After resolution of bacteriuria and acute cys-
titis in mice, a small population of UPEC persists within uroepi-
thelial cells. These bacteria resist immune clearance and systemic
antimicrobial therapy and can reemerge to cause same-strain re-
current cystitis even if antimicrobials have symptomatically re-
solved the initial episode. More recent studies have suggested that
a combined exfoliant/antimicrobial approachmight help to erad-
icate these chronically resident bacteria (15). This approach, if
translated to a population ofwomenwith recurrent cystitis, would
markedly impact themorbidity of this recalcitrant condition. Pre-
liminary work indicates that the exfoliants presented here exhibit
antibacterial effect against UPEC at relatively high concentrations
(e.g., 50 M; data not shown). In addition to this potential
FIG 7 Recovery of bladder epithelium following exfoliation. Bladders were treated in vivo with protamine sulfate (PS) or compound 2, 3, or 9 (800 M) as
indicated. One week after inoculation, the mice were euthanized, and their bladders were processed for standard histology. Within this interval after treatment
with any of these exfoliants, a histologically normal uroepithelium is regenerated atop the basement membrane, including the presence of multinucleate facet
cells. Bar, 50 m.
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intrinsic antibacterial use, these exfoliants could be chemically
modified with biocides (e.g., silver cation) or delivered in con-
junction with existing antimicrobials to interrupt this cycle of re-
current infection or to prevent UTI, for instance, following uri-
nary tract instrumentation.
More challenging is the clinical investigation and preclinical
modeling of urologic chronic pelvic pain syndromes, including
chronic bladder pain, interstitial cystitis, and chronic prostatitis
(33). These conditions confer burdensome symptoms to many
patients, and as the causes are poorly understood, directed and
evidence-based management options are lacking. However, there
is evidence that exfoliation of the superficial bladder epithelium
mightmitigate pain associated with these conditions (29). In part,
this may be because the uroepithelial cells represent a primary
source of proinflammatory cytokines and chemokines in bladder
inflammatory responses. Thus, while one might at first glance ex-
pect that intentional uroepithelial exfoliationwould be inflamma-
tory, the approach may in fact curtail inflammation and provide
analgesia (29). Our cytokine data also support the lack of signifi-
cant inflammation associated with exfoliation.
A further application of urinary bladder exfoliation would be
in the diagnosis and treatment of bladder cancer, specifically tran-
sitional cell carcinoma. Uroepithelial cancers can be diagnosed by
cystoscopy and biopsy but also noninvasively by urine cytology.
The sensitivity of cytology may be augmented with the use of
either monoclonal antibodies to detect carcinoma antigens or flu-
orescent in situ hybridization probes for chromosomal abnormal-
ities found in bladder carcinoma (reviewed in reference 34). In
addition, postresection monitoring in bladder cancer patients
may involve both cytology and other biomarker-based methods
(e.g., detection of nuclear matrix protein 22). However, the utility
of these newer approaches is not universally accepted, especially
across distinct patient populations and clinical situations (35),
and additional biomarkers and methodologies are under study.
Topical administration of an exfoliant would provide a much
richer sample for cytologic analysis, likely increasing the sensitiv-
ity of cell-based diagnostics. In addition, as mentioned above, the
chemical scaffold presented here could, hypothetically, be modi-
fied to target the exfoliant more specifically to carcinoma cells.
Overall, imidazolium salt-based uroepithelial exfoliants have a
number of potential applications in both UTI and noninfectious
conditions of the urinary tract.
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